What changed in Nutex Health, Inc.'s 10-K — 2024 vs 2025
Paragraph-level year-over-year comparison of Nutex Health, Inc.'s 2024 and 2025 10-K annual filings, covering the Business, Risk Factors, Legal Proceedings, Cybersecurity, MD&A and Market Risk sections. Every new, removed and edited paragraph is highlighted side-by-side so you can see exactly what management changed in the 2025 report.
Top changes in Nutex Health, Inc.'s 2025 10-K
548 paragraphs added · 422 removed · 284 edited across 8 sections
- Item 1A. Risk Factors+230 / −168 · 111 edited
- Item 1. Business+140 / −117 · 84 edited
- Item 7. Management's Discussion & Analysis+117 / −113 · 68 edited
- Item 3. Legal Proceedings+25 / −2 · 1 edited
- Item 5. Market for Registrant's Common Equity+20 / −7 · 6 edited
Item 1. Business
Business — how the company describes what it does
84 edited+56 added−33 removed42 unchanged
Item 1. Business
Business — how the company describes what it does
… 93 more changes not shown on this page.
Item 1A. Risk Factors
Risk Factors — what could go wrong, per management
111 edited+119 added−57 removed93 unchanged
Item 1A. Risk Factors
Risk Factors — what could go wrong, per management
… 207 more changes not shown on this page.
Item 1C. Cybersecurity
Cybersecurity — threats and controls disclosure
10 edited+2 added−1 removed3 unchanged
Item 1C. Cybersecurity
Cybersecurity — threats and controls disclosure
Item 2. Properties
Properties — owned and leased real estate
2 edited+0 added−0 removed1 unchanged
Item 2. Properties
Properties — owned and leased real estate
Item 3. Legal Proceedings
Legal Proceedings — active lawsuits and investigations
1 edited+24 added−1 removed0 unchanged
Item 3. Legal Proceedings
Legal Proceedings — active lawsuits and investigations
Item 5. Market for Registrant's Common Equity
Market for Common Equity — stock, dividends, buybacks
6 edited+14 added−1 removed4 unchanged
Item 5. Market for Registrant's Common Equity
Market for Common Equity — stock, dividends, buybacks
Item 7. Management's Discussion & Analysis
Management's Discussion & Analysis (MD&A) — revenue / margin commentary
68 edited+49 added−45 removed23 unchanged
Item 7. Management's Discussion & Analysis
Management's Discussion & Analysis (MD&A) — revenue / margin commentary
… 82 more changes not shown on this page.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Market Risk — interest-rate, FX, commodity exposure
2 edited+0 added−0 removed0 unchanged
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Market Risk — interest-rate, FX, commodity exposure